Heron Therapeutics, Inc. (Nasdaq: HRTX) reported preliminary, unaudited fourth quarter and full-year 2025 net revenue totaling approximately $40.5 million and $154.9 million, respectively. The growth was driven by products like ZYNRELEF® and APONVIE®. ZYNRELEF® saw a significant revenue increase of approximately 35% in Q4 2025 compared to Q3 2025. The company focuses on developing and commercializing therapeutic innovations to improve medical care. These products aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.

Read more at GlobeNewswire: Heron Therapeutics Announces Preliminary, Unaudited Q4 and